|
| Interactions: | Acenocoumarol Adverse Effect an increased risk of bleedingClinical Management In patients receiving oral anticoagulation, the prothrombin time (PT) or international normalized ratio (INR) should be closely monitored with the addition and withdrawal of treatment with nonsteroidal antiinflammatory drugs (NSAIDs), including fenoprofen. Coagulation parameters should also be reassessed periodically during concurrent therapy. Adjustments of the acenocoumarol dose may be necessary in order to maintain the desired level of anticoagulation
Amiloride Adverse Effect reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicityClinical Management When administering Nabumetone and Amiloride concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels
AmlodipineAdverse Effect An increased risk of gastrointestinal hemorrhageClinical Management Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Ardeparin Adverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employedClinical Management Patients receiving Ardeparin and Nabumetone should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to Ardeparin . Nabumetone should be discontinued several days prior to surgery.
Atenolol Adverse Effect Decreased antihypertensive effectClinical Management If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
Atenolol Comb.Adverse Effect Decreased antihypertensive effectClinical Management If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
Benazepril Adverse Effect Decreased antihypertensive and natriuretic effectsClinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.
BetaxololAdverse Effect Decreased antihypertensive effectClinical Management If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
Bisoprolol Adverse Effect Decreased antihypertensive effectClinical Management If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
Bumetanide Adverse Effect decreased diuretic and antihypertensive efficacyClinical Management When administering Bumetanide and Nabumetone concurrently, monitor blood pressure and weight. Also, follow the patient for decreased urine output and increased edema.
Captopril Adverse Effect Decreased antihypertensive and natriuretic effectsClinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.
Captopril Comb. Adverse Effect Decreased antihypertensive and natriuretic effectsClinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.
Carvedilol Adverse Effect Decreased antihypertensive effectClinical Management If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
CeliprololAdverse Effect Decreased antihypertensive effectClinical Management If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
Chlorpropamide Adverse Effect A possible increased risk of hypoglycemiaClinical Management When Nabumetone is coadministered with Chlorpropamide , patients should be monitored more closely for hypoglycemia. Dose of Chlorpropamide may need to be reduced when Nabumetone is added to therapy.
Chlorthalidone Adverse Effect Decreased diuretic and antihypertensive efficacyClinical Management When administering thiazide diuretics and nonsteroidal antiinflammatory agents (NSAIDs) concurrently, monitor blood pressure and weight. Also, follow the patient for decreases in urine output and increased edema.
Clopamide Adverse Effect Decreased diuretic and antihypertensive efficacyClinical Management When administering thiazide diuretics and nonsteroidal antiinflammatory agents (NSAIDs) concurrently, monitor blood pressure and weight. Also, follow the patient for decreases in urine output and increased edema.
Dalteparin Adverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employedClinical Management Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
Diltiazem Adverse Effect An increased risk of gastrointestinal hemorrhageClinical Management Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
EnalaprilAdverse Effect Decreased antihypertensive and natriuretic effectsClinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.
Enalapril Comb. Adverse Effect Decreased antihypertensive and natriuretic effectsClinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.
EnoxaparinAdverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employedClinical Management Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
EsmololAdverse Effect Decreased antihypertensive effectClinical Management If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
FelodipineAdverse Effect An increased risk of gastrointestinal hemorrhageClinical Management Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
FlunarizineAdverse Effect An increased risk of gastrointestinal hemorrhageClinical Management Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
FrusemideAdverse Effect decreased diuretic and antihypertensive efficacyClinical Management When administering Frusemide and Nabumetone concurrently, monitor blood pressure and weight. Also, follow the patient for decreased urine output and increased edema.
Glibenclamide Adverse Effect A possible increased risk of hypoglycemiaClinical Management When Nabumetone is coadministered with Glibenclamide drug, patients should be monitored more closely for hypoglycemia. Dose of Glibenclamide may need to be reduced when Nabumetone is added to therapy.
GliclazideAdverse Effect A possible increased risk of hypoglycemiaClinical Management When Nabumetone is coadministered with Gliclazide , patients should be monitored more closely for hypoglycemia. Dose of Gliclazide may need to be reduced when Nabumetone is added to therapy.
GlimepirideAdverse Effect A possible increased risk of hypoglycemiaClinical Management When Nabumetone is coadministered with Glimepiride , patients should be monitored more closely for hypoglycemia. Dose of Glimepiride may need to be reduced when Nabumetone is added to therapy.
Glipizide Adverse Effect A possible increased risk of hypoglycemiaClinical Management When Nabumetone is coadministered with Glipizide , patients should be monitored more closely for hypoglycemia. Dose of Glipizide may need to be reduced when Nabumetone is added to therapy.
IndapamideAdverse Effect Decreased diuretic and antihypertensive efficacyClinical Management When administering thiazide diuretics and nonsteroidal antiinflammatory agents (NSAIDs) concurrently, monitor blood pressure and weight. Also, follow the patient for decreases in urine output and increased edema.
Ketorolac Adverse Effect enhanced gastrointestinal adverse effects (peptic ulcers, gastrointestinal bleeding and/or perforation)Clinical Management Concomitant use of ketorolac and other nonsteroidal antiinflammatory agents is contraindicated.
LMWH sod.salt Adverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employedClinical Management Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
Labetalol Adverse Effect Decreased antihypertensive effectClinical Management If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
Lacidipine Adverse Effect An increased risk of gastrointestinal hemorrhageClinical Management Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
LevobunololAdverse Effect Decreased antihypertensive effectClinical Management If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
Lisinopril Adverse Effect Decreased antihypertensive and natriuretic effectsClinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.
LithiumAdverse Effect Lithium toxicity (weakness, tremor, excessive thirst, confusion)Clinical Management Serum lithium levels should be monitored within the first few days if a nonsteroidal antiinflammatory drug is added or discontinued from therapy, and periodically thereafter. Patients should be followed for any symptoms of toxicity; a decrease in the lithium dose is often required with concomitant therapy.
Methotrexate Adverse Effect methotrexate toxicity (leukopenia, thrombocytopenia, anemia, nephrotoxicity, mucosal ulcerations)Clinical Management In general, do not administer NSAIDS within 10 days of high-dose methotrexate (ie, doses used in cancer therapy).
Metoprolol Adverse Effect Decreased antihypertensive effectClinical Management If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
Metoprolol Comb. Adverse Effect Decreased antihypertensive effectClinical Management If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
Nadroparin Adverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employedClinical Management Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
Nifedipine Adverse Effect An increased risk of gastrointestinal hemorrhageClinical Management Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
NimodipineAdverse Effect an increased risk of gastrointestinal hemorrhageClinical Management Patients who are receiving concurrent Nabumetone and Nimodipine should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Nitrendipine Adverse Effect An increased risk of gastrointestinal hemorrhageClinical Management Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Ofloxacin Adverse Effect an increased risk of seizuresClinical Management Ofloxacin should be used cautiously in patients receiving other medications which may lower the seizure threshold, including nonsteroidal antiinflammatory drugs (NSAIDs). Alternative therapy should be considered, especially in patients who are predisposed to seizure activity.
Oxprenolol Adverse Effect Decreased antihypertensive effectClinical Management If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
Perindopril Adverse Effect Decreased antihypertensive and natriuretic effectsClinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.
Phenindione Adverse Effect An increased risk of bleedingClinical Management Although nabumetone has been shown to have less effect on platelet aggregation and to cause less gastric erosion than other nonsteroidal antiinflammatory drugs (NSAIDs), caution should still be exercised when using nabumetone and Phenindione together. Coagulation parameters should be monitored with the addition and withdrawal of nabumetone therapy, and should be reassessed periodically during concurrent treatment. Adjustments of the phenindione dose may be necessary in order to maintain the desired level of anticoagulation. Clinicians and patients should be aware of the increased potential for bleeding, especially from the gastrointestinal tract, during concomitant therapy.
Pindolol Adverse Effect Decreased antihypertensive effectClinical Management If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
Propranolol Adverse Effect Decreased antihypertensive effectClinical Management If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
Propranolol Comb. Adverse Effect Decreased antihypertensive effectClinical Management If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
Ramipril Adverse Effect Decreased antihypertensive and natriuretic effectsClinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.
Ramipril Comb.Adverse Effect Decreased antihypertensive and natriuretic effectsClinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.
Reviparin Adverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employedClinical Management Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
Sotalol Adverse Effect Decreased antihypertensive effectClinical Management If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
SpironolactoneAdverse Effect reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicityClinical Management When administering Nabumetone and Spironolactone concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels
Timolol Adverse Effect Decreased antihypertensive effectClinical Management If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
Tinzaparin Adverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employedClinical Management Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
Tolbutamide Adverse Effect A possible increased risk of hypoglycemiaClinical Management When Nabumetone is coadministered with Tolbutamide , patients should be monitored more closely for hypoglycemia. Dose of Tolbutamide may need to be reduced when Nabumetone is added to therapy.
Verapamil Adverse Effect An increased risk of gastrointestinal hemorrhageClinical Management Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Warfarin Adverse Effect An increased risk of bleedingClinical Management Although nabumetone has been shown to have less effect on platelet aggregation and to cause less gastric erosion than other nonsteroidal antiinflammatory drugs (NSAIDs), caution should still be exercised when using warfarin and nabumetone concurrently. Coagulation parameters should be monitored with the addition and withdrawal of nabumetone therapy, and should be reassessed periodically during concurrent treatment. Adjustments of the warfarin dose may be necessary in order to maintain the desired level of anticoagulation. Clinicians and patients should be aware of the increased potential for bleeding, especially from the gastrointestinal tract, during concomitant therapy.
Xipamide Adverse Effect Decreased diuretic and antihypertensive efficacyClinical Management When administering thiazide diuretics and nonsteroidal antiinflammatory agents (NSAIDs) concurrently, monitor blood pressure and weight. Also, follow the patient for decreases in urine output and increased edema. |
|
|